|
Health Condition(s) or Problem
|
Leukemia; Lymphoma
|
|
Lay Summary
|
RATIONALE: Less intensive therapy may attain in the same results as intensive therapy in
children with non-Hodgkin's lymphoma.
PURPOSE: Randomized phase III trial to study the effectiveness of less intensive therapy for
children who have non-Hodgkin's lymphoma.
(from ClinicalTrials.gov)
|
|
Who can enter the trial
|
DISEASE CHARACTERISTICS:
- One of the following diagnoses:
- Newly diagnosed B-cell non-Hodgkin's lymphoma in Revised European-American
Lymphoma (REAL) categories II 9, 10, and 11, i.e.:
- Diffuse large cell
- Burkitt's
- High-grade B-cell, Burkitt's-like
- L3 leukemia with greater than 5% blasts in bone marrow
- No anaplastic large cell Ki1-positive lymphomas
- Immunophenotype and Murphy stage required prior to randomization
PATIENT CHARACTERISTICS:
Age:
- Over 6 months to under 21 years
- Maximum age 18 years in France and the United Kingdom
Other:
- No congenital immunodeficiency
- No prior organ transplantation
- No prior malignancy
- Not HIV positive
- Available for at least 36 months of follow-up
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy
Endocrine therapy:
- Steroids initiated no more than 72 hours prior to entry allowed
- Bone marrow and cerebrospinal fluid examination required prior to steroids
Radiotherapy:
- Emergency radiotherapy initiated no more than 72 hours prior to entry allowed
Surgery:
- Not specified
|
|
Who cannot enter the trial
|
DISEASE CHARACTERISTICS:
- One of the following diagnoses:
- Newly diagnosed B-cell non-Hodgkin's lymphoma in Revised European-American
Lymphoma (REAL) categories II 9, 10, and 11, i.e.:
- Diffuse large cell
- Burkitt's
- High-grade B-cell, Burkitt's-like
- L3 leukemia with greater than 5% blasts in bone marrow
- No anaplastic large cell Ki1-positive lymphomas
- Immunophenotype and Murphy stage required prior to randomization
PATIENT CHARACTERISTICS:
Age:
- Over 6 months to under 21 years
- Maximum age 18 years in France and the United Kingdom
Other:
- No congenital immunodeficiency
- No prior organ transplantation
- No prior malignancy
- Not HIV positive
- Available for at least 36 months of follow-up
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy
Endocrine therapy:
- Steroids initiated no more than 72 hours prior to entry allowed
- Bone marrow and cerebrospinal fluid examination required prior to steroids
Radiotherapy:
- Emergency radiotherapy initiated no more than 72 hours prior to entry allowed
Surgery:
- Not specified
|
|
What will happen
|
Biological; filgrastim; Drug; CHOP regimen; Drug; cyclophosphamide; Drug; cytarabine; Drug; doxorubicin hydrochloride; Drug; etoposide; Drug; leucovorin calcium; Drug; methotrexate; Drug; prednisolone; Drug; prednisone; Drug; therapeutic hydrocortisone; Drug; vincristine sulfate
|
|
Primary aim
|
Sorry, not currently available
|
|
Secondary Aim
|
Sorry, not currently available
|
|
Participant Information Sheet
|
Sorry, not currently available
|
|
Website
|
http://cancer.gov/clinicaltrials/COG-C5961
|
|
Recruitment Status
|
Not Recruiting
|
|
Nation
|
England
|
|
Location
|
Sheffield
|